Covixyl-V Nasal Spray Reviews: Can It Be Trusted For Real?

The active ingredient in Spray Covixyl-V is Ethyl LauroylArginate Hydrochloride (ELAH), which has been certified as a "Generally Recognized as Authorized" (GRAS) component by the Food and Drug Administration (FDA) and is safe to use in food and other over-the-counter items in the US, EU, UK, and Germany. Human clinical trials, in addition to in vitro and in vivo research, were successfully completed to establish the safety and effectiveness of Covixyl-V nasal spray. Action Mechanism: COVIXYL-V kills the virus by limiting its replication in the nasal tissues (if the virus does not attach, it is washed away by mucous secretions). It aids in the natural elimination of the inactivated virus by blowing one's nose or creating the usual nasal secretions. Ethyl LauroylArginate Hydrochloride (ELAH), the active ingredient in COVIXYL-V, is a Generally Recognized as Safe (GRAS) component recognised by the Food and Drug Administration (FDA) for use in food and other over-the-counter items in the US, EU, UK, and Germany. Clinical Investigation: In vitro studies using the rVSV-SARS-CoV-2 model indicated that the virus is 99.99% inhibited at low doses. According to in vivo studies done by a BSL-3 laboratory using the Syrian hamster model, the same animal used by Pfizer and Modena for vaccine development, COVID-19 is 99.99% inactivated, and no negative effects were seen after injection. There are three stages to using it: Spray two to three times into each nostril. The ELAH (Ethyl LauroylArginate HCL) formulation reduces viral adhesion to the nasopharynx, hence restricting virus development and dissemination. Remove: Due to the action of normal secretion, the inactivated virus moves spontaneously from the nasopharynx outward to the nose or inward to the stomach. The nasal spray works by forming a physical barrier that stops the virus from attaching to the surface of the nasopharynx. This barrier mechanism has been confirmed in vitro by a prominent BSL-3 facility in Wyoming. Because the nasopharynx has been identified as the virus' principal entry point, employing the nasal spray is mostly successful. The revolutionary COVIXYL-V technology has been granted a PCT international patent (PT/US20/55772). ELAH has been the subject of several in vitro and in vivo studies to establish its toxicity, metabolism, and efficiency. These studies confirmed that it had no negative effects on human metabolism, pharmacology, or immunology. After being granted pre-emergency use permission, this medicine is seeking FDA approval for commercial use in the United States.